EUROPEAN HEREDITARY TUMOUR GROUP (EHTG)

Mallorca Group

Final Program

6th Meeting of the European Hereditary Tumour Group (EHTG)

Thursday, Sept. 29 - Saturday Oct. 1st 2022

PLSD

The Prospective Lynch Syndrome Database

Hybrid Meeting -

F2F and live virtual in Palma de Mallorca

EUROPEAN HEREDITARY TUMOUR GROUP

Invitation

Dear members, friends, affiliates and sponsors,

we are absolutely delighted to invite you to join us for this hybrid meeting and share with you the program of the 6th EHTG meeting 2022 in beautiful Palma de Mallorca. While all meetings are better in person, if you cannot come to Mallorca you can enjoy much of the program via the live virtual format.

Day one (Thursday) and day 3 (Saturday) will be F2F and live virtual. The same applies for Friday, our dedicated working group (WG) day, however, only one of three parallel working groups will be F2F and live virtual, whereas the other two in parallel will be live virtual only. There are limited on-site places for F2F participants in Mallorca for the entire meeting and these will be prioritized for accepted and invited speakers and chairs, followed by allocation on a „first come first get registration“ basis, so please register as soon as you can to avoid disappointment.

As always, our main focus will be to discuss the newest hot topics in all areas of research and clinical management for patients with hereditary cancer predisposition syndromes.

This year there are some new topical highlights, such as showcasing of the best abstracts in the plenary sessions.

Join us in the debates that will be on controversial and provocative topics!

Importantly, this year will offer an open platform to patient societies for networking. We wish to promote international collaboration in this field and hope that many patients and patient societies will get in touch and join us in person or virtually in Palma.

Please visit the website **www.ehtg.org** for more information and contact **gs007@ehtg.org** for all organizational issues and any of the board members if you have any suggestions.

Kind regards

Your EHTG Board

Organisation

Board Members:
Aysel Ahadova, Germany
Peter Bauerfeind, Switzerland
John Burn, United Kingdom
Mev Dominguez-Valentin, Norway
Fiona Lalloo, United Kingdom
Gabriela Möslein, Germany
Pål Møller, Norway
Julian Sampson, United Kingdom
Toni Seppälä, Finland
Rolf Sijmons, Netherlands
Sanne ten Broeke, Netherlands

Program Committee:
Chair: Mev Dominguez-Valentin, Norway
Toni Seppälä, Finland
Aysel Ahadova, Germany
Y-EHTG (Young.EHTG): Sanne ten Broeke, Netherlands

Secretariat:
Gabriele Sponholz
Gs007@ehtg.org
+49 (0)160 8459502

Location:
SCAN ME
Hybrid – F2F and **live virtual** in Palma de Mallorca at the Hotel Victoria Gran Meliá, with additional live streaming and online participation, post meeting on demand version for members

Registration: Only online via **www.ehtg.org**

Registration fees: See website

Certification: EACCME® accreditation by UEMS, total of 19 CME credit points (THU: 6 / FRI: 8 / SAT: 5)

Sponsors: The event is sponsored by the following companies or institutions:

Main sponsors: PROMEGA Corporation 10.000 EUR
Promega
PAICON GmbH 8.000 EUR
PAICON
Further sponsor: Ovesco 1.000 EUR
ovesco innovation in scope

Content

Day 1 (Thursday, September 29th)

F2F and live virtual

08:00 - 10:00 a.m.	Registration
10:00 - 11:00 a.m.	The 12 best visual posters
11:00 - 11:30 a.m.	Coffee break
11:30 a.m. - 01:30 p.m.	Plenary Session 1 (6 talks)
01:30 - 02:30 p.m.	Lunch Symposium
02:30 - 03:30 p.m.	Big Debate 1
03:30 - 04:30 p.m.	Big Debate 2
04:30 - 05:00 p.m.	Coffee break
05:00 - 06:00 p.m.	Evolving Technologies
06:00 - 07:00 p.m.	Welcome Reception

Day 2 (Friday, September 30th)

F2F and live virtual
(3 x 3 parallel WGs – 1 F2F, 2 live virtual only)

08:00 - 09:00 a.m.	PLSD Meeting
09:00 - 11:00 a.m.	3 parallel Working Groups
11:00 - 11:30 a.m.	Coffee break
11:30 a.m. - 01:30 p.m.	3 parallel Working Groups
01:30 - 2:30 p.m.	Lunch
02:30 - 04:30 p.m.	3 parallel Working Groups
End of scientific program	
04:30 - 06:00 p.m.	FAP Guidelines (by invitation only)
07:00 p.m. - open end	Congress Dinner (Social Program)

Day 3 (Saturday, October 1th)

F2F and live virtual

09:00 - 11:00 a.m.	WG Reporting Back Session and Collaborative Studies
11:00 - 11:30 a.m.	Coffee break
11:30 a.m.- 12:45 p.m.	Hot Topics
12:45 - 01:30	Networking with patient organizations
01:30 - 02:30 p.m.	EHTG Business Meeting
02:30 - 03:15 p.m.	Big Debate 3
03:15 - 03:45 p.m.	Best of Abstracts
03:45 - 04:30 p.m.	Big Debate 4
04:30 p.m.	Farewell
04:45 - 11:00 p.m.	Excursion (Social Program) with Dinner

General remarks:

The meeting will be a plenary F2F meeting (with live-streaming) in the conference rooms of the beautiful Hotel Gran Melia Victoria in Palma de Mallorca. On Thursday, Sept. 29, there will be a plenary sessions day, same as on Saturday, October 1. On Friday, we have planned the Working Group day with a total of 9 (3x3) parallel working groups, of which a total of three successive working groups will be F2F in the conference meeting room. 2 parallel working groups throughout the day (3 x 2) will be a virtual meeting, of course with live interaction.

Notes

08:00-10:00 a.m. **REGISTRATION on siteplace**

10:00-11:00 a.m. **The 12 best visual posters (3* + 2' each)**

Chairs:
Winship, Ingrid (Australia)
Haupt, Saskia(Germany)

1. *Clinicopathological Features of Deficient Mismatch Repair (dMMR) Protein Expression Patterns in Colorectal Cancer in a Spanish Cohort*
   Suárez Sánchez, Aida (Spain)

2. APC mosaicism is a relevant explanation in (mild) polyposis phenotypes
   Nielsen, Maartje (Netherlands)

3. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: a retrospective analysis from the Finnish national Lynch syndrome research registry
   Zalevskaja, Kristina (Finland)

4. HLA-specific immunogenicity of Lynch Syndrome associated frameshift peptide neoantigens – towards next-generation cancer vaccines
   Hernandez Sanchez, Alejandro (Germany)

5. Molecular carcinogenesis pathway of MLH1-associated Lynch syndrome colorectal cancer unraveled: "two-in-one hit" model
   Ahadova, Aysel (Germany)

6. The prevalence of mismatch repair deficiency in ovarian cancer: systematic-review and metanalysis
   Ryan, Neil (UK)

7. Detection of mismatch repair deficiency in colonoscopic biopsies and urine using a simple PCR multiplex with potential for postal urinary tumour surveillance in Lynch syndrome patients
   Phelps, Rachel (UK)

8. Genetic testing in early onset colorectal cancer: experience of an oncogenetic consultation in the era of NGS sequencinig
   Farelly, Solenne (France)

9. Lynch Syndrome is associated with fecal and salivary dysbiosis
   Mannucci, Alessandro (Italy)

10. Why the combination of modeling and machine learning could be the future direction in mathematical oncology
    Haupt, Saskia (Germany)

11. The Person-Based Approach to optimising a personalised, interactive patient decision aid for people with Lynch syndrome
    Kohut, Kelly (UK)

12. Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (MesaCAPP)
    Backman, Ann-Sofie (Sweden)

11:00-11:30 a.m. **COFFEE BREAK**

11:30 a.m.-01:30 p.m. **Plenary Session 1**

Chairs: *Annika Auranen (Finland), Yurgelun, Matthew (USA), Scharl, Michael (Switzerland)*

1. Protecting fertility in patients with hereditary cancer syndromes
   Auranen, Annika (Finland)
2. What do the patients value in risk management – a patient association perspective
   Reents, Nicola (Germany)
3. What do the patients value in risk management – a cancer family perspective
   Dubin, Dave (USA)
4. Cancer vaccines
   Vilar, Eduardo (USA)
5. Immune surveillance and immune prevention in Lynch syndrome – new evidence for the feasibility of cancer-preventive vaccines
   Kloor, Matthias (Germany)
6. Clinical description and first estimates of age-associated cancer risk and survival in the context of constitutional mismatch repair system deficiency (CMMRD syndrome): report from the European database of the European consortium C4CMMRD
   Robbe, Julie (France)

01:30-02:30 p.m. **LUNCH Symposium / LUNCH BOX**

PAICON: A Digital Ecosystem Tailored for Doctors and Researchers
Ratnaparkhe, Manasi (Germany)

02:30-03:30 p.m. **Big Debate 1**

Chairs: *Buchanan, Dan (Australia), Ahadova, Aysel (Germany)*

Systematic testing should be implemented for all cancers for acquired (somatic) and germline (inherited) genetic variants

Speakers: *Winship, Ingrid (Australia), Sijmons, Rolf (Netherlands)*

Discussion

03:30-04:30 p.m. **Big Debate 2**

Chair: *Levi, Zohar (Israel), Colas, Chrystelle (France)*

The term of oligopolyposis serves no purpose

Speakers: *Half, Elizabeth (Israel), Nielsen, Maartje (Netherlands)*

Discussion

04:30-05:00 p.m. **COFFEE BREAK**

05:00-06:00 p.m. Evolving Technologies: applications of AI / machine learning

Chairs: *Backman, Ann-Sophie (Sweden), von Knebel Doeberitz, Magnus* (Germany)

1. AI-assisted Pathology
   Kather, Jakob Niklas (Germany)
2. AI-assisted Endoscopy
   Messmann, Helmut (Germany)
3. AI-assisted radiology/nuclear medicine
   Hüllner, Martin (Switzerland)

06:00-07:00 p.m. **WELCOME RECEPTION on the MELIA Victoria hotel terrace**

08:00-09:00 a.m.: PLSD Meeting

08:00-08:15 a.m. **Abstract session**

Chair: *Dominguez-Valentin, Mev*

1. *Møller, Pål*: Lynch Syndrome: Which cancer comes first?
2. *Møller, Pål*: The four Lynch syndromes
3. *Møller, Pål*: An additional carcinogenetic mechanism for colon cancer in Lynch syndrome

08:15-09:00 a.m. **OPEN PLSD Business Meeting**

Chair: *Møller, Pål*

Agenda including ongoing and suggested studies and administrative matters to be voted on at business meeting will be circulated to all local responsible contributors prior to the meeting, while the meeting is open for all interested to attend.

09:00-11:00 a.m. Parallel Working Groups

09:00-11:00 a.m. WG 8 – F2F

Surgery and Gastroenterology

Chairs: *Moeslein,Gabriela (Germany)*
Bauerfeind, Peter (Switzerland)

Speaker: *Manucci, Alessandro*
"Duodenal Polyposis in FAP and revision of the Spigelman Classification"

1. Is there a correlation between genotype and duodenal phenotype in Familial Adenomatous Polyposis?
   D'Hooge, Marion (Italy)
2. Duodenal disease in 579 individuals with MUTYH-associated polyposis: updated findings from an international prospective observational study
   Truscott, Becky (UK)
3. Small bowel cancer in patients with Familial Adenomatous Polyposis – report of two clinical cases and review of literature
   Colletti, Gaia (Italy)
4. Ileoanal pouch cancers in Ulcerative Colitis and Familial Adenomatous Polyposis: A systematic review and meta-analysis
   Pellino, Gianluca (Italy)
5. Metachronous CRC after surgery in Lynch Syndrome
   Seppälä, Toni (Finland)
6. Functional Outcome Differences between Males and Females Who have Undergone Reconstructive Surgery with Ileorectal Anastomoses (IRA) or Ileal Pouch-Anal Anastomoses (IPAA) due to Familial Adenomatosis Polyposis - A Prospective Cohort Study
   Mira, Daniel (Sweden)
7. Real-time use of artificial intelligence (CADEYE) in colorectal cancer surveillance of patients with Lynch syndrome – a randomized controlled pilot trial (CADLY)
   Hüneburg, Robert (Germany)

09:00-11:00 a.m. WG 1 – virtual

Carcinogenic mechanism and pathways

Chairs: *Sampson, Julian (UK),*
ten Broeke, Sanne (Netherlands)

Speaker: *de Voer, Richarda (Netherlands)*
MBD4: the new kid on the BER-deficiency block

1. Clinicopathological Features of Deficient Mismatch Repair (dMMR) Protein Expression Patterns in Colorectal Cancer in a Spanish Cohort
   Suárez Sánchez, Aida (Spain)
2. Constitutional MLH1 methylation, frequency and mode of identification
   Dardenne, Antoine (France)
3. Genome-wide methylome of Lynch syndrome and Familial adenomatous polyposis-associated colorectal tumors
   Mäki-Nevala, Satu (Finland)
4. Germline MBD4 mutations in cancer predisposition
   Valle, Laura (Spain)
5. HLA-specific immunogenicity of Lynch Syndrome associated frameshift peptide neoantigens – towards next-generation cancer vaccines
   Hernandez Sanchez, Alejandro (Germany)
6. Molecular carcinogenesis pathway of MLH1-associated Lynch syndrome colorectal cancer unraveled: “two-in-one hit” model
   Ahadova, Aysel (Germany)
7. APC mosaicism is a relevant explanation in (mild) polyposis phenotypes
   Nielsen, Maartje (Netherlands)

Program Friday, September 30th, 2022

09:00-11:00 a.m. WG 3 – virtual

Epidemiology of hereditary cancer

Chairs: *Jenkins, Mark (Australia)*
Engel, Christoph (Germany)

Speaker: *Heinimann, Karl (Switzerland)*
Prevalence of pathogenic variants in hereditary cancer by whole exome / genome analysis

1. Cancer mortality by organ, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early diagnosis and treatment: A report from the Prospective Lynch Syndrome Database
   Dominguez-Valentin, Mev (Norway)
2. Central Amalgamation of a nationally complete registry of Lynch Syndrome carriers in England
   Huntley, Catherine (UK)
3. Germline Mismatch Repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996-2020: development of a national resource of patient-level genomics laboratory records
   Turnbull, Clare (UK)
4. Implementation of population-wide effective CRC screening for Lynch syndrome using the MSI-Plus Assay
   Herrero Belmonte, Patricia (UK)
5. The English National Lynch syndrome transformation project: An NHS Genomic Medicine Service Programme
   Monahan, Kevin (UK)
6. Universal Testing of Asturian Population Diagnosed with Lynch Syndrome
   Díaz Vico, Tamara (Spain)

11:00-11:30 a.m. **COFFEE BREAK**

11:30 a.m.-01:30 p.m. Parallel Working Groups

11:30 a.m.-01:30 p.m. WG 9 – F2F

Systemic biomarkers

Chairs: *Dominguez-Valentin, Mev (Norway)*
Ahadova, Aysel (Germany)

Speaker: *Perea Garcia, José (Spain)*
Update of the recent advances in liquid biopsy in colorectal cancer management

1. Combined somatic copy number alteration and fragmentation analysis for treatment monitoring in colorectal cancer patients using liquid biopsy
   Hallermayr, Ariane (Germany)
2. A Demonstration of Microsatellite Instability Analysis with Circulating Tumor DNA in Endometrial Cancer
   Lewis, Samantha (USA)
3. Analysis of plasma cell-free DNA genome-wide methylation in colorectal cancer and adenoma patients - towards a cell-free DNA-based surveillance
   Eikenboom, Ellis (Netherlands)
4. Associations of circulating microRNAs with body mass index, waist circumference, and physical activity in Lynch syndrome
   Sievänen, Tero (Finland)
5. Highly sensitive Liquid Biopsy Duplex Sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants
   Romic-Pickl, Julia (Germany)
6. Whole-exome sequencing of cell-free DNA reveals mutational signatures associated with Lynch syndrome
   Kauma, Iiro (Finland)

Program Friday, September 30th, 2022

11:30 a.m.-01:30 p.m. WG 6 – virtual

Risk and Clinical Management

Chairs: *Lubinski, Jan (Poland)*
Dueñas Cid, Nuria (Spain)

Speaker: *Snowsill, Tristan (UK)*
Surveillance for gynaecological cancers in Lynch syndrome – lessons from a UK health technology assessment and next steps

1. The Person-Based Approach to optimising a personalised, interactive patient decision aid for people with Lynch syndrome
   Kohut, Kelly (UK)
2. Uncertainty quantification in oncology - How do uncertain data influence model results and clinical decision making?
   Zeilmann, Alexander (Germany)
3. From Diagnosis of Colorectal cancer to Diagnosis of Lynch Syndrome: The RM Partners Quality Improvement Project
   Monje-Garcia, Laura (UK)
   Koziel, Ana (UK)
4. Improvement of IAFLD under TEDUGLUTIDE in a patient with familiary adenomatous polyposis (FAP) and short bowel syndrome
   Bauerfeind, Peter (Switzerland)
5. Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (MesaCAPP)
   Backman, Ann-Sofie (Sweden)
6. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: a retrospective analysis from the finnish national Lynch syndrome research registry
   Zalevskaja, Kristina (Finland)

11:30 a.m.-01:30 p.m. WG 2 – virtual

Early onset cancers

Chairs: *Perea Garcia, José (Spain)*
Valle, Laura (Spain)

Speaker: *Cavestro, Giulia Martina (Italy)*

DIRECT: Delphi initiative for EoCRC. CGA-IGC, EHTG, AIFET Guidelines for the Management of Early-Onset Colorectal Cancer

1. Genetic testing in early onset colorectal cancer: experience of an oncogenetic consultation in the era of NGS sequencinig
   Farelly, Solenne (France)
2. Young-onset gastric cancers are often early gastric cancers
   Puzzono, Marta (Italy)
3. Comprehensive characterization of hereditary cancer cases from Peru: Bringing precision medicine to a low-resource setting
   Dominguez-Valentin, Mev (Norway)
4. Germline pathogenic variants detected in microsatellite-instable cancers: a two-year prospective experience from a Hungarian center
   Grolmusz, Vince Kornél (Hungary)

01:30-02:30 p.m. **LUNCH**

02:30-04:30 p.m. Parallel Working Groups

Program Friday, September 30th, 2022

02:30-04:30 p.m. WG 4 – F2F

Genetics & Counselling

Chairs: *Sijmons, Rolf (Netherlands)*
Hampel, Heather (USA)

Speaker: *Nakken, Sigve (Norway)*
Interpretation of cancer-predisposing germline variants with Cancer Predisposition Sequencing Reporter (CPSR)

1. A national picture of molecular testing for Lynch syndrome in England highlights gaps in testing and opportunities for improved diagnosis
   McRonald, Fiona (UK)
2. A nurse led genetic clinic for Lynch syndrome testing in colorectal cancer 1 year later
   Langford, Lora (UK)
   Proserpio, Mauro (UK)
3. APC-specific ACMG/AMP variant classification guideline alleviates the burden of variants of uncertain significance in ClinVar and locus-specific databases
   Aretz, Stefan (Germany)
4. Targeted short-read RNA sequencing as supplement to DNA germline testing to increase diagnostic yield
   Wendlandt, Martin (Germany)
5. Existing with a cancer ghost in the back of my mind- Written narratives of living with Lynch syndrome
   Eriksen, Elin O. (Norway)
6. Mutational and transcriptomic landscape and somatic evolution in Li-Fraumeni Syndrome-associated tumourigenesis
   Torra I Benach, Maria (UK)
7. Psychological well-being of people living with a colorectal cancer predisposition syndrome: evidence from a systematic review
   Monje-Garcia, Laura (UK)

02:30-04:30 p.m. WG 5 – virtual

Novel associations

Chairs: *Therkildsen, Christina (Denmark),*
Møller, Pål (Norway)

Speaker: *Valle, Laura (Spain),*
Wnt signaling genes as cause of serrated polyposis

1. High Prevalence of MUTYH Associated Polyposis Among Minority Populations in Israel, due to Rare Founder Pathogenic Variants
   Reznick Levi, Gili (Israel)
2. Lynch Syndrome is associated with fecal and salivary dysbiosis
   Mannucci, Alessandro (Italy)
3. Oligodontia-colorectal cancer syndrome with cleft palate as a possible new feature in a cohort of 13 AXIN2 variant carriers
   Roht, Laura (Estonia)
4. The Impact of Oophorectomy on Survival from Breast Cancer in Patients with CHEK2 Mutations
   Lubinski, Jan (Poland)
5. Why the combination of modeling and machine learning could be the future direction in mathematical oncology
   Haupt, Saskia (Germany)
6. Clinically relevant combined effect of polygenic background, rare pathogenetic germline variants, and family history on colorectal cancer incidence
   Aretz, Stefan (Germany)

Program Friday, September 30th, 2022

02:30-04:30 p.m. WG 7 – virtual

Screening in gynecology, urology and beyond

Chairs: *Ryan, Neil (UK)*
Nebgen, Denise R. (USA)

Speaker: *Nebgen, Denise R. (USA)*
Should women with Lynch syndrome be offered gynecological cancer surveillance?

1. Hypercalcemic Ovarian carcinoma and mutation of SMARCA4: we need early testing
   Perez-Lopez, Maria-Eva (Spain)
2. The prevalence of mismatch repair deficiency in ovarian cancer: systematic-review and metanalysis
   Ryan, Neil (UK)
3. The genomic and clinico-pathological characteristics of sebaceous skin lesions from people with Lynch syndrome
   Buchanan, Dan (Australia)
4. Detection of mismatch repair deficiency in colonoscopic biopsies and urine using a simple PCR multiplex with potential for postal urinary tumour surveillance in Lynch syndrome patients
   Phelps, Rachel (UK)
5. Distinguishing the molecular profile of endometrial cancer by spectroscopy: A Diagnostic Cross-Sectional Study
   Ryan, Neil (UK)
6. NON-BRCA mutation prevalence in hereditary breast and ovarian cancer syndrome in our centre
   Jimenez Ruiz, Francisco Javier (Spain)

04:30 p.m. **End of congress day for all non-participants of FAP Guidelines**

04:30-06:30 p.m. FAP Guidelines (by invitation only) **F2F and virtual**

07:30 p.m. – OPEN END: CONFERENCE DINNER

Program Saturday, October 1st, 2022

09:00-11:00 a.m. **WG Reporting Back Session and Collaborative Studies**

Chairs: *Sijmons, Rolf (Netherlands), Ryan, Neil (UK)*

11:00-11:30 a.m. **COFFEE BREAK**

11:30 a.m.-12:45 p.m. **Hot Topics**

Chairs: *Aretz, Stefan (Germany), Seppäla, Toni (Finland)*

1. Challenges of organizing European patient cancer registries for research
   Speaker: *Hoogerbrugge, Nicoline (Netherlands)*
   (on behalf of ERN GENTURIS)
2. ESCP/EHTG – Joint symposium; Topic: PD-1 blockade in mismatch repair-deficient cancer
   Introduction: *Doulias, Triantafillos (USA)*
   Speaker: *Shiu, Kai-Keen (UK)*
   Discussant: *Burn, John (UK)*

12:45-01:30 p.m. **Networking with patient organizations**

Organizer: *Reents, Nicola (Germany)*
Chairs: *Moeslein, Gabriela (Germany)*
Sijmons, Rolf (Netherlands)

Living with Lynch / Polyposis: patient perspective and best practices across Europe

1. Semi-Colon patient advocacy group
   Lutter, Heidi (Germany)
   Widhalm, Simone (Germany)
2. Lynch Syndrome UK
   Secret, Pamela (UK)
3. FAPA Belgium
   Sanctorum, Katlijn (Belgium)
4. Colores
   Tamminen, Jenni (Finland)
   Linden, Mia (Finland)
5. Lynch+Polyposis syndromes
   van Roijen, Ron (Netherlands)
   van de Sande, Frans-Willem (Netherlands)

Program Saturday, October 1st, 2022

01:30-02:30 p.m. **EHTG Business Meeting & LUNCH BOX**

02:30-03:15 p.m. **Big Debate 3**

Chairs: *Capella, Gabriel (Spain) / Parc, Yann (France)*

Aspirin prevents more LS colorectal cancers than endoscopy

Speakers: *Burn, John (UK), Rösch, Thomas (Germany)*

Discussion

03:15-03:45 p.m. **Best of abstracts**

Chair: *Kloor, Matthias (Germany)*

1. Assessment of the ability of the polygenic background to refine colorectal cancer risk in Lynch syndrome
   Dueñas Cid, Nuria (Spain)
2. Mutation rate evolution drives immune escape in mismatch repair-deficient cancer
   Jansen, Marnix (UK)

03:55-04:30 p.m. **Big Debate 4**

Chairs: *Scharl, Michael (Switzerland) Scott, Rodney (UK)*

Molecular testing can direct management of colorectal cancer

Speakers: *Pellino, Gianluca (Italy), Seppälä, Toni (Finland)*

Discussion

04:30 p.m. **Farewell**
Moeslein, Gabriela (Germany)

ca. 5 p.m. **Optional: Bus excursion**

Speakers List

Ahadova, Aysel
University Hospital Heidelberg & DKFZ, Heidelberg, Germany

Aretz, Stefan
University Hospital Bonn, Bonn, Germany

Auranen, Annika
University of Turku, Turku, Finland

Backman, Ann-Sofie
Karolinska University Hospital, Stockholm, Sweden

Bauerfeind, Peter
Hirslanden Klinik St. Anna, Zürich, Switzerland

Buchanan, Dan
University of Melbourne, Melbourne, Australia

Burn, John
Newcastle University, Newcastle Upon Tyne, United Kingdom

Capella, Gabriel
Catalan Institute of Oncology, IDIBELL, Barcelona, Spain

Cavestro, Giulia Martina
Vita-Salute San Raffaele University, Milano, Italy

Colas, Chrystelle
Institut Curie, Paris, France

Colletti, Gaia
Evangelisches Bethesda Krankenhaus, Duisburg, Germany

Dardenne, Antoine
APHP, Paris, France

De Voer, Richarda
Radboud UMC, Nijmegen, Netherlands

D'Hooge, Marion
Hôpital Cochin, Paris, France

Díaz Vico, Tamara
Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain

Dominguez-Valentin, Mev
Oslo University Hospital, Oslo, Norway

Doulias, Triantafillos
Colchester Hospital University, Colchester, USA

Dubin, Dave
AliveAndKickn, USA

Dueñas Cid, Nuria
Hospital Duran i Reynals, Barcelona, Spain

Speakers List

Eikenboom, Ellis
Erasmus Medical Center, Rotterdam, Netherlands

Engel, Christoph
Universität Leipzig, Leipzig, Germany

Eriksen, Elin O.
Haukeland University Hospital, Bergen, Norway

Farelly, Solenne
Hôpital Cochin, Paris, France

Grolmusz, Vince Kornél
National Institute of Oncology, Budapest, Hungary

Half, Elizabeth
Rambam Health Care Campus, Haifa, Israel

Hallermayr, Ariane
MGZ Medical Center of Genetics, München, Germany

Hampel, Heather
Ohio State University, USA

Haupt, Saskia
Heidelberg University & HITS, Heidelberg, Germany

Heinimann, Karl
University Hospital Basel, Basel, Switzerland

Hernandez Sanchez, Alejandro
German Cancer Research Center (DKFZ), Heidelberg, Germany

Herrero Belmonte, Patricia
NHS, Newcastle Upon Tyne, United Kingdom

Hoogerbrugge, Nicoline
Radboud UMC, Nijmegen, Netherlands

Hüllner, Martin
University Hospital Zürich, Zürich, Switzerland

Hüneburg, Robert
University Hospital Bonn, Bonn, Germany

Huntley, Catherine
Institute of Cancer Research, London, United Kingdom

Jansen, Marnix
UCL Cancer Institute, London, United Kingdom

Jenkins, Mark
University of Melbourne, Melbourne, Australia

Jimenez Ruiz, Francisco Javier
Hospital Juan Ramon Jimenez, Huelva, Spain

Speakers List

Kather, Jakob Niklas
Technical University Dresden, Dresden, Germany

Kauma, Iiro
University of Helsinki, Helsinki, Finland

Kloor, Matthias
University Hospital Heidelberg & DKFZ, Heidelberg, Germany

Kohut, Kelly
University of Southampton, Southampton, United Kingdom

Koziel, Ana
The St Mark's Hospital Harrow, United Kingdom

Langford, Lora
Imperial College Healthcare NHS Trust, London, United Kingdom

Levi, Zohar
RMC, Israel, Petach Tikva, Israel

Lewis, Samantha
Promega Corporation, Madison, Wi, USA

Lubinski, Jan
Pomeranian Medical University, Szczecin, Poland

Mäki-Nevala, Satu
University of Helsinki, Helsinki, Finland

Mannucci, Alessandro
Vita-Salute San Raffaele University Milano, Italy

McRonald, Fiona
National Disease Registration Service (NDRS), NHS Digital, Birmingham, United Kingdom

Messmann, Helmut
Augsburg University, Augsburg, Germany

Mira, Daniel
Karolinska Institutet, Stockholm, Sweden

Møller, Pål
The Norwegian Radium Hospital, Oslo, Norway

Monahan, Kevin
Imperial College London, London, United Kingdom

Monje-Garcia, Laura
The St Mark's Centre, London, United Kingdom

Möslein, Gabriela
Evangelisches Bethesda Krankenhaus, Duisburg, Germany

Nakken, Sigve
University of Oslo, Oslo, Norway

Speakers List

Nebgen, Denise R.
University of Texas MD Anderson Cancer Center, USA

Nielsen, Maartje
LUMC, Leiden, Netherlands

Parc, Yann
Sorbonne University, Hôpital Saint-Antoine, Paris, France

Pellino, Gianluca
Università degli Studi della Campania „Luigi Vanvitelli", Naples, Italy

Perea Garcia, José
Madrid Hospital Vithas, Madrid, Spain

Perez-Lopez, Maria-Eva
University of Santiago de Compostela, Santiago de Compostela, Spain

Phelps, Rachel
Newcastle University, Newcastle Upon Tyne, United Kingdom

Puzzono, Marta
Università Vita-Salute San Raffaele, Milano, Italy

Ratnaparkhe, Manasi
PAICON, Heidelberg, Germany

Reents, Nicola
SemiColon, Bonn, Germany

Reznick Levi, Gili
Rambam Health Care Campus, Haifa, Israel

Robbe, Julie
Institut Curie, Paris

Roht, Laura
Tartu University Hospital, Tartu, Estonia

Romic-Pickl, Julia
Medical Genetics Center Munich, Munich, Germany

Rösch, Thomas
Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany

Ryan, Neil
University of Bristol, Bristol, United Kingdom

Sampson, Julian
Cardiff University, Cardiff, United Kingdom

Scharl, Michael
Universitätsspital Zürich, Zürich, Switzerland

Scott, Rodney
University of Newcastle, Newcastle Upon Tyne, United Kingdom

Speakers List

Seppälä, Toni
Tampere University, Tampere, Finland

Shiu, Kai-Keen
University College London Hospital, London, United Kingdom

Sievänen, Tero
University of Jyväskylä, Jyväskylä, Finland

Sijmons, Rolf
University Medical Center Groningen, Groningen, Netherlands

Snowsill, Tristan
University of Exeter, Exeter, United Kingdom

Suárez Sánchez, Aida
HUCA, Oviedo, Spain

ten Broeke, Sanne
University Medical Center Groningen, Groningen, Netherlands

Therkildsen, Christina
Copenhagen University Hospital, Hvidovre, Denmark

Torra I Benach, Maria
University of Cambridge, United Kingdom

Truscott, Becky
Cardiff University Barnham, Cardiff, United Kingdom

Turnbull, Clare
ICR - The Institute of Cancer Research, London, United Kingdom

Valle, Laura
Catalan Institute of Oncology, IDIBELL, Barcelona, Spain

Vilar, Eduardo
The University of Texas MD Anderson Cancer Center (Houston, Texas), USA

von Knebel Doeberitz, Magnus
University Hospital Heidelberg & DKFZ, Heidelberg, Germany

Wendlandt, Martin
Medical Genetics Center Munich, Munich, Germany

Winship, Ingrid
University of Melbourne, Melbourne, Australia

Yurgelun, Matthew
Dana Farber Cancer Institute, Boston, USA

Zalevskaja, Kristina
Helsinki University Hospital, Helsinki, Finland

Zeilmann, Alexander
HITS & Heidelberg University, Heidelberg, Germany

Imprint

Responsible in accordance with press law:

Prof. Dr. med. Gabriela Moeslein
Evangelisches Bethesda Krankenhaus
Zentrum für Hereditäre Tumorerkrankungen
47053 Duisburg
g.moeslein@bethesda.de

Ethical MedTech
MedTech Europe compliance portal

The 2022 EHTG Meeting has been judged COMPLIANT by the MedTech Europe Code of Ethical Business Practice

EUROPEAN HEREDITARY TUMOUR GROUP